905994-07-2

Basic information

• Product Name: C₂₈H₃₅FN₄O₈S
• CAS NO: 905994-07-2
• Molecular Weight: 606.672
• Mol File: 905994-07-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: C₂₈H₃₅FN₄O₈S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₃₅FN₄O₈S(905994-07-2)
• EPA Substance Registry System: C₂₈H₃₅FN₄O₈S(905994-07-2)

Safety Data

• Hazardous Substances Data: 905994-07-2(Hazardous Substances Data)

Usage

General Description

The chemical C28H35FN4O8S is a compound with the formula representing its 28 carbon, 35 hydrogen, 4 nitrogen, 8 oxygen, and 1 sulfur atoms. This chemical compound is likely a complex organic molecule with a fluorine atom attached to one of its carbon atoms. It may contain various functional groups such as amine, carboxyl, and sulfate groups. Its specific properties, uses, and characteristics would depend on its molecular structure and the specific arrangement of atoms within the molecule.

Upstream product

• 159622-10-3 (1R,2S)-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 1374041-49-2 C₁₇H₂₂BrNO₅ 
• 1374041-50-5 C₂₆H₂₈BrFN₂O₆ 
• 630421-48-6 tert-butyl ((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate 
• 1013925-90-0 (2S,4R)-4-(4-fluoro-1,3-dihydro-isoindole-2-carbonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 154350-29-5 cyclopropanesulphonamide 
• 1152020-87-5 C₂₅H₃₀FN₃O₇ 
• 127168-78-9 4-fluoro-2,3-dihydro-1H-isoindole 

Relevant articles and documents

HCV NS3 PROTEASE INHIBITORS

The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.

HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the c

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.